Second, constructed biologic subtype represented a significant predictor for the incidence of subsequent distant dissemination; non-Rec+/HER2- patients had significantly worse 5-year DMFS, indicating that non-Rec+/HER2- breast cancer might be more aggressive and prone to metastasize. This evidence concerns the gene ERBB2 and breast carcinoma.